LLY vs. JNJ, MRK, ABBV, NVO, AZN, NVS, UNH, TMO, PFE, and BMY
Should you be buying Eli Lilly and Company stock or one of its competitors? The main competitors of Eli Lilly and Company include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Novartis (NVS), UnitedHealth Group (UNH), Thermo Fisher Scientific (TMO), Pfizer (PFE), and Bristol-Myers Squibb (BMY). These companies are all part of the "medical" sector.
Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership.
Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.2%. Eli Lilly and Company pays an annual dividend of $5.20 per share and has a dividend yield of 0.7%. Johnson & Johnson pays out 30.9% of its earnings in the form of a dividend. Eli Lilly and Company pays out 76.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has increased its dividend for 63 consecutive years and Eli Lilly and Company has increased its dividend for 10 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Johnson & Johnson has higher revenue and earnings than Eli Lilly and Company. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Johnson & Johnson has a net margin of 45.26% compared to Johnson & Johnson's net margin of 17.08%. Johnson & Johnson's return on equity of 56.98% beat Eli Lilly and Company's return on equity.
Eli Lilly and Company received 89 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 70.07% of users gave Eli Lilly and Company an outperform vote while only 64.95% of users gave Johnson & Johnson an outperform vote.
In the previous week, Eli Lilly and Company had 6 more articles in the media than Johnson & Johnson. MarketBeat recorded 48 mentions for Eli Lilly and Company and 42 mentions for Johnson & Johnson. Eli Lilly and Company's average media sentiment score of 0.69 beat Johnson & Johnson's score of 0.51 indicating that Johnson & Johnson is being referred to more favorably in the media.
Johnson & Johnson presently has a consensus price target of $175.86, suggesting a potential upside of 13.72%. Eli Lilly and Company has a consensus price target of $769.53, suggesting a potential downside of 0.06%. Given Eli Lilly and Company's higher possible upside, equities research analysts plainly believe Johnson & Johnson is more favorable than Eli Lilly and Company.
Johnson & Johnson has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.
Summary
Johnson & Johnson beats Eli Lilly and Company on 12 of the 21 factors compared between the two stocks.
Get Eli Lilly and Company News Delivered to You Automatically
Sign up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eli Lilly and Company Competitors List
Related Companies and Tools
